Why Exact Sciences (EXAS) Dipped More Than Broader Market Today

Market Performance - Exact Sciences (EXAS) closed at $63 22, with a -1% movement compared to the previous day, lagging behind the S&P 500's daily loss of 0 58% [1] - Over the past month, shares of Exact Sciences gained 3 17%, outperforming the Medical sector's loss of 6 07% and the S&P 500's loss of 1 09% [1] Earnings and Revenue Expectations - Exact Sciences is expected to post earnings of -$ 0 50 per share in its upcoming earnings report on May 8, 2024, marking a year-over-year decline of 19 05% [1] - The Zacks Consensus Estimate for revenue projects net sales of $624 95 million, up 3 73% from the year-ago period [1] - For the entire year, the Zacks Consensus Estimates forecast earnings of -$ 0 86 per share and revenue of $2 83 billion, indicating changes of +23 89% and +13 32%, respectively, compared to the previous year [2] Analyst Estimates and Revisions - Recent changes to analyst estimates for Exact Sciences should be noted, as positive alterations signify analyst optimism regarding the company's business and profitability [2] - The Zacks Consensus EPS estimate has remained unchanged over the last 30 days [3] Industry and Zacks Rank - Exact Sciences presently features a Zacks Rank of 2 (Buy) [3] - The Medical - Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 82, placing it in the top 33% of all 250+ industries [3] - The Zacks Industry Rank shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [3]